Search company, investor...

Peptonic Medical


Series A | Alive

Total Raised


About Peptonic Medical

Peptonic Medical is developing estrogen-free pharmaceuticals for treatment of vaginal atrophy. The patented treatments are based on local, vaginal application of oxytocin. The company's vision is to make the naturally occurring hormone, oxytocin, into the leading treatment for women suffering from vaginal atrophy during menopause. Four different clinical studies have been performed. Three of which were randomized, double blind, and placebo controlled. The studies have shown positive effects on local signs of vaginal atrophy within the vaginal wall and a reduction of symptoms.

Headquarters Location

Gustavslundsvägen 143

Bromma, 167 51,


+46 (0)470 57 11 10

Missing: Peptonic Medical's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Peptonic Medical's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Peptonic Medical

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Peptonic Medical is included in 2 Expert Collections, including Women's Health & Wellness.


Women's Health & Wellness

1,484 items

Startups focused on providing products and services catering to women's health and wellbeing.


Medical Devices

3,088 items

Companies that have been granted at least 1 510(k) by the FDA since 2014. Companies tagged as #FDA510(K)

Peptonic Medical Patents

Peptonic Medical has filed 2 patents.

The 3 most popular patent topics include:

  • Estranes
  • Estrogens
  • Gynaecology
patents chart

Application Date

Grant Date


Related Topics



Psychiatric diagnosis, Gynaecology, Estrogens, Estranes, Syndromes


Application Date


Grant Date


Related Topics

Psychiatric diagnosis, Gynaecology, Estrogens, Estranes, Syndromes



Latest Peptonic Medical News

Peptonic signs distributor agreement with Windsor Pharmaceutical

Jan 24, 2023

PEPTONIC Medical AB Tue, Jan 24, 2023 14:59 CET Peptonic Medical (publ) today informed the company has signed an exclusive distributor agreement for Central Amerika with Windsor Pharmaceutical concerning the companys vaginal self tests Peptonic has signed an exclusive distributor agreement with Windsor Pharmaceutical for countries in Central America. The contract spans over four years and includes Peptonic Medical self tests for vaginal infections and amniotic leakage. The products will be sold under Windsor Pharmaceuticals own brand Amniotest. Windsor Pharmaceutical is a pharmaceutical company founded 2016 with a specific focus on women’s health in Central America. The company has an extensive experience of registering as well as getting reimbursement for its range of products. -          We are very pleased with having landed an agreement with Windsor Pharmaceutical. That the products have gotten reimbursement and will be readily available for women with an early launch is very exciting, say’s Erik Sundquist CEO of Peptonic Medical -          Peptonic Medical has a very interesting range of self tests which we are very excited to build the business for in a region where we have very extensive experience of women’s health and hospital health care systems, says Christian Naumann, CEO and Founder of Windsor Pharmaceutical VagiVital VS is a clinically proven self test that diagnoses vaginal infection with 92% accuracy. The test is carried out on vaginal fluid and indicates the answer within 30 seconds. VagiVital AL is a clinically proven self test that can detect amniotic leakage with 97% accuracy. The test consists of a pantyliner with a patented biofilm on its surface. The result is indicated with a color change 15 minutes after the pantyliner has become wet. Peptonic continues to meet strong interest from international distributors concerning its clinically proven vaginal self tests. The agreement with Windsor is additional evidence that the company’s solutions are sought after and another quality stamp of its medical device products. The launch is expected in q2 this year. Erik Sundquist, CEO E-post: ABOUT Peptonic Medical AB Peptonic is a Swedish innovative biomedical company that conducts research, development and sales of medical treatments and lifestyle products in the field of women's health. Peptonic has divided its operations into two business areas: "Medical Consumer" and "Lifestyle Consumer". The business area "Medical Consumer" is based on clinically proven intimate self-care and constitutes the company's main focus and is sold under the VagiVital brand. The "Lifestyle Consumer" business area consists of lifestyle products with a focus on sustainable menstrual products and is sold under the Lunette brand. The company was founded in 2009 and the stock has been traded since 2014 on Spotlight ( in Stockholm

Peptonic Medical Frequently Asked Questions (FAQ)

  • Where is Peptonic Medical's headquarters?

    Peptonic Medical's headquarters is located at Gustavslundsvägen 143, Bromma.

  • What is Peptonic Medical's latest funding round?

    Peptonic Medical's latest funding round is Series A.

  • How much did Peptonic Medical raise?

    Peptonic Medical raised a total of $2.1M.

  • Who are the investors of Peptonic Medical?

    Investors of Peptonic Medical include Almi Invest.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.